Knochenbeteiligung beim Multiplen Myelom und anderen Tumorerkrankungen: Von Bisphosphonaten zu zielgerichteten Therapien

Zentrale Themen des 2. Internationalen Myelom-Workshops waren Pathogenese, Diagnostik und Therapie des Multiplen Myeloms. Den besonderen Aspekt der Knochenbeteiligung diskutierten interdisziplinär Hämatologen und Onkologen, Strahlentherapeuten, Radiologen, Orthopäden und Kieferspezialisten (Tab. 1).

• Literatur

• 1 Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma.. Clin Cancer Res 2011; 17 (06) 1278-1286.
• 2 Engelhardt M. et al. Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma.. Anticancer Res 2009; 29 (11) 4745-4750.
• 3 Moulopoulos LA. et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.. J Clin Oncol 1995; 13 (01) 251-256.
• 4 Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease.. J Clin Oncol 2011; 29 (14) 1907-1915.
• 5 Moulopoulos LA. et al. Multiple myeloma: MR patterns of response to treatment.. Radiology 1994; 193 (02) 441-446.
• 6 Dimopoulos M. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.. Leukemia 2009; 23 (09) 1545-1556.
• 7 Hussein MA. et al. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.. Leukemia 2008; 22 (08) 1479-1484.
• 8 Morgan GJ. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.. Lancet 2010; 376 9757 1989-1999.
• 9 Gnant M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.. N Engl J Med 2009; 360 (07) 679-691.
• 10 Treister N, Woo SB. Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw.. N Engl J Med 2006; 355 (22) 2348.
• 11 Henry DH. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.. J Clin Oncol 2011; 29 (09) 1125-1132.
• 12 Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.. Leukemia 2007; 21 (09) 1875-1884.